Skip to main content

Day: January 4, 2024

Zerify Provides 2024 Projections and Updates on Recently Announced Transactions-Deals

EDISON, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) — Zerify Inc. (OTC PINK: ZRFY), a pioneer in cybersecurity specializing in secure video conferencing and endpoint security, is delighted to present its revenue projection for 2024. Additionally, the company offers the latest updates on recently disclosed transactions and deals. Mark L. Kay, CEO of Zerify expressed his enthusiasm for the company’s trajectory, highlighting, “We are extremely optimistic about both our company’s future and that of our shareholders. Our Zerify Meet & Defender technologies represent the most groundbreaking innovations in the video conferencing market over the past two decades. We firmly believe that no other company in this industry can match the competitive advantages we possess.” “That’s why in 2024 Zerify is projecting $3.9M...

Continue reading

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 03 01 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases.Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. Inflammasome ASC Inhibitor IC 100, designed to inhibit multiple inflammasome pathways to attenuate initiation and perpetuation of damaging inflammation pathogenic in numerous inflammatory diseases.WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Noble Capital Markets has initiated company-sponsored equity...

Continue reading

Soda Ash Market Size Worth USD 32.30 Billion in 2032 | Emergen Research

Rising demand for soda ash from detergent and soap industries and increasing need for soda ash in the glass industry are key factors driving soda ash market revenue growth Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) — The global soda ash market size was USD 19.95 Billion in 2022 and is expected to register a rapid revenue CAGR of 4.9% during the forecast period. The driving forces behind this growth include the escalating demand for soda ash in detergent and soap industries, coupled with a rising need within the glass sector. Soda ash is an essential ingredient in the manufacturing of powdered detergents and soaps owing to their potent alkalinity and surfactant qualities, which improves detergent’s solubility and effectiveness in removing stains while using less water. Several laundry and cleaning product formulations include...

Continue reading

Antiaging Market Size Worth USD 381.11 Billion in 2032 | Emergen Research

Rising awareness about beauty in aging population and increasing accessibility of beauty products and services are key factors driving market revenue growth Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) — The global antiaging market size was USD 189.50 billion in 2022 and is expected to register a rapid revenue CAGR of 7.3% during the forecast period. Rising awareness about beauty in aging population and increasing accessibility of beauty products and services are key factors driving market revenue growth. The demand for antiaging products has witnessed a surge, particularly among women who prioritize health and skin beauty. The market is also driven by the rising income levels, improving living standards, and a global shift towards prioritizing physical appearance. According to the United Nations World Population Prospects 2022, by...

Continue reading

Active Pharmaceutical Ingredients Market Size Worth USD 329.80 Billion in 2032 | Emergen Research

Rising demand for pharmaceutical drugs and increasing drug Research & Development (R&D) activities are key factors driving Active Pharmaceutical Ingredients (API) market revenue growth Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) — The global Active Pharmaceutical Ingredients (API) market, valued at USD 144.70 Billion in 2022, is poised to experience a rapid revenue Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period. This surge is attributed to the escalating demand for pharmaceutical drugs and the intensification of Research & Development (R&D) activities within the sector. APIs, the active components of drugs, are gaining prominence as a key player in the cure, mitigation, treatment, and prevention of diseases. The market’s growth is further fueled by the rising prevalence of chronic...

Continue reading

Form 8.3 – [LXi REIT PLC – 03 01 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LXi REIT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

— Phase 3 hypothalamic obesity top-line data expected in 1H2025 — — Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain — — IND application for RM-718 accepted by the FDA — BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today provided a business update and announced it has completed screening for enrollment in the pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity. Rhythm closed screening and anticipates overenrolling the ongoing phase 3 hypothalamic...

Continue reading

Lands’ End Launches Exclusive Women’s Swimwear Collection at Target

The swim line was designed exclusively for TargetLands’ EndLands’ End Exclusive Women’s Swim Collection at TargetDODGEVILLE, Wis., Jan. 04, 2024 (GLOBE NEWSWIRE) — Lands’ End, the classic American lifestyle brand today announced an exclusive women’s swim collection of nearly 70 pieces, including tops, bottoms, skirts, cover-ups, and bags. Ranging in price from $36-$70, the collection incorporates new Lands’ End fabrics, prints, patterns, and colors all with the brand’s trusted quality. As two leading retailers, Lands’ End and Target teamed up to offer a swim assortment that delivers relevant style, premium solutions, and inclusive designs for customers. The collection at Target incorporates Lands’ End’s quintessential features such as sun protection rated UPF50+, slimming Slendertex fabric, and built...

Continue reading

New Era Helium Corp. to List on NASDAQ Through Merger with Roth CH Acquisition V Co.

Combination Is Expected to Value New Era Helium Corp at $90 Million Pre-Money MIDLAND, Texas and NEWPORT BEACH, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — New Era Helium Corp. (“NEH” or the “Company”), an exploration and production (“E&P”) company that sources helium produced in association with the production of natural gas reserves in North America, and Roth CH Acquisition V Co. (NASDAQ: ROCL) (“Roth CH V” or “ROCL”), a publicly-traded special purpose acquisition company, announced today the signing of a definitive agreement for a business combination at a pre-money valuation of $90 million, that is expected to result in NEH becoming a public company. Upon the closing of the transaction, subject to approval by ROCL’s stockholders and other customary closing conditions, the combined company will be named “New Era Helium Corp.”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.